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Objectives. Retroperitoneal lymph node dissection (RPLND) outcomes for testis cancer originate mostly from single-center series.
Wecharacterizedpopulation-basedutilization,costs,andoutcomesandassessedwhetherhighervolumeaﬀectsoutcomes.Methods
and Materials. Using the US Nationwide Inpatient Sample from 2001–2008, we identiﬁed 993 RPLND and used propensity
score methods to assess utilization, costs, and inpatient outcomes based on hospital surgical volume. Results. 51.6% of RPLND
were performed at hospitals where there were two or fewer cases per year. RPLND was more commonly performed at large
urban teaching hospitals, where men were younger, more likely to be white and earning incomes exceeding the 50th percentile
(all P ≤ .05). Higher hospital volumes were associated with fewer complications and more routine home discharges (all
P ≤ .047). However, higher volume hospitals had more transfusions (P = .004) and incurred $1,435 more in median costs
(P<. 001). Limitations include inability to adjust for tumor characteristics and absence of outpatient outcomes. Conclusions.
Sociodemographic diﬀerences exist between high versus low volume RPLND hospitals. Although higher volume hospitals had
more transfusions and higher costs, perhaps due to more complex cases, they experienced fewer complications. However, most
RPLND are performed at hospitals where there were two or fewer cases per year.
1.Introduction
Testis cancer is the most common malignancy among US
men aged 18–34 years. The overall incidence of germ cell tu-
mors has risen since 1973, and the annual increase in the
incidence of nonseminomatous germ cell tumors (NSGCT-)
has been 2% per year [1, 2]. Retroperitoneal lymph node dis-
section (RPLND) is used for the treatment of men with stage
INSGCT, low volume stageII disease, and in thepostchemo-
therapy setting to eradicate residual mass. However, RPLND
utilization has decreased since 1988 due to the increased use
of surveillance and primary chemotherapy [3].
Due to the relative low incidence of testis cancer com-
paredwithothergenitourinarymalignancies,mostreportsof
RPLND use and outcomes originate from high volume ter-
tiary referral centers, and there is an absence of population-
based RPLND outcomes data. While testis cancer mortality
and RPLND use rates have been reported from the U.S.
Surveillance Epidemiology and End Results (SEER) cancer
registry [3], there is currently no way to link pathologic data
to nationally representative administrative datasets such as
Medicare, due to the age limitation of this patient popula-
tion. Moreover, while volume outcomes eﬀects have been
characterized for oncologic procedures, leading to advocacy
for selective referral to high volume centers to improve out-
comes and decrease costs [4], there is a dearth of RPLND
testis cancer volume outcomes studies. This is particularly
important because this is a complex, potentially morbid
operation that aﬀects otherwise healthy young men. Our
objectives are to characterize population-based RPLND2 Advances in Urology
utilization, costs, and inpatient outcomes and to assess the
eﬀect of hospital RPLND surgical volume on outcomes.
2. MaterialsandMethods
2.1. Study Cohort. We analyzed the US Healthcare Cost and
Utilization Project (HCUP) Nationwide Inpatient Sample
(NIS), from the Agency for Healthcare Research and Quality,
between 2001 and 2008. NIS is a 20% stratiﬁed probability
sample that encompasses hospitals in 42 states with approxi-
mately8millionacutehospitalstaysfromover1000hospitals
peryear.Itisthelargestall-payerinpatientcareobservational
cohort in the US and represents approximately 90% of all
hospital discharges.
Using International Classiﬁcation of Diseases, 9th Edi-
tion (ICD-9) procedure codes, we identiﬁed RPLND (ICD-9
40.29, 40.3, 40.52, 40.59, 59.00) associated with a diagnosis
of testis cancer (ICD-9 186x) in men aged ≥18 years during
this period [5]. RPLND associated with laparoscopic (ICD-
9 54.21, 54.51) and robotic (ICD-9 17.4x) approaches were
identiﬁed, however, these 29 cases were excluded from the
ﬁnal cohort due to inability to power-adjusted analyses. We
excluded subjects with hospital admissions for metastatic
testis cancer: multiple sites of malignancy (ICD-9 196.x,
197.x, 198.x, 199.x, 202.x), chemotherapy administration
(ICD-999.25,99.28,V58.1x,E933.1),orautologousstemcell
transplant (ICD-9 41.04). Moreover, because NIS does
not characterize tumor stage, we excluded more complex
RPLND performed concurrently with radical orchiectomy
(ICD-9 62.3; n = 67), nephrectomy (ICD-9 55.5, 55.51; n =
27), or both orchiectomy and nephrectomy (n suppressed
p e rN I Sf o r0<n<11) from our primary analysis to limit
heterogeneity of comparison. However, as a subanalysis, we
separately characterized diﬀerences in outcomes and costs by
RPLND complexity.
2.2. Independent Variables. Due to the low incidence of
testis cancer and RPLND, we used unweighted NIS sampling
frequencies per HCUP recommendation. We examined pa-
tient (age, race, comorbidities [6], ZIP code-based median
income, and primary payer) and hospital (US census region,
urban versus rural location, teaching status, and bed size)
level characteristics that may inﬂuence outcomes.
Of the 3726 hospitals sampled by the NIS from 2001–
2008, 1469 (39%) treated adults with testis cancer, and 420
( 1 1 % )p e r f o r m e do n eo rm o r eR P L N D .W ec a t e g o r i z e dh i g h
volume hospitals ap r i o r ias those exceeding the 90th per-
centile in terms of annual procedural volume. With 33 of 62
hospitalsperformingonlyoneRPLNDthatyear,thisresulted
inahighvolumedesignationofthreeormoreRPLNDversus
a low volume designation of one to two RPLND. Addition-
ally, we characterized volume as a continuous variable.
2.3. Outcomes. ICD-9 diagnosis and procedure codes were
used to identify outcomes of interest: blood transfusions and
complications (cardiac, respiratory, genitourinary, vascular,
wound, miscellaneous medical, and miscellaneous surgical)
[7]. (See the Supplementary Material S1 available online at:
doi:10.1155/2012/189823.) NIS-speciﬁc outcomes included
death, length of hospital stay (LOS), discharge disposition
(routine (home) versus other (home healthcare, rehabilita-
tion, skilled nursing facility, etc.)), and costs. Costs were
derived from inpatient charges using the HCUP cost-to-
charge ratio [8], and we quantiﬁed the eﬀect of complica-
tions on hospital costs and LOS.
2.4. Statistical Analysis. Propensity score weighting [9, 10]
was used to control for potential confounders among treat-
ment groups, where the confounders included patient race,
primary payer, income, and comorbidity, and hospital type,
bed size, and geographic region. Each patient was weighted
by the inverse propensity (or probability) of being in the
treatment group, with the goal of balancing characteristics
between groups. The propensity of being in each treatment
group was calculated using multivariate logistic regression
models based on the above potential confounders. All anal-
yses were two sided and performed with SAS version 9.2
(SAS Institute Inc, Cary, North Carolina, U.S.A.) and were
considered signiﬁcant at P ≤ .05.
3. Results
3.1. Characteristics of Study Sample. We identiﬁed 993 men
who underwent RPLND with a median age of 29 years
(Table 1), the majority of whom was white (61.8%), with
no or few comorbidities (85.8%) and were privately insured
(71.4%). RPLND were mostly performed at urban teaching
hospitals (79.6%) and large bed size facilities (78.7%).
512 (51.6%) of cases were performed at low volume
hospitals where there were two or fewer RPLND per year.
MenundergoingRPLNDathighversuslowvolumehospitals
were younger, more likely to be white and earning incomes
exceeding the 50th percentile (Table 1,a l lP ≤ .05). High
v o l u m eR P L N Dh o s p i t a l sw e r em o r el i k e l yt ob eu r b a n
teaching hospitals with greater bed capacity (both P<. 001).
No diﬀerences were observed by hospital volume in terms of
geographic region or patient comorbidity.
3.2. Outcomes. Unadjusted and propensity adjusted out-
comes were similar. To demonstrate raw counts for clinical
interpretability, we present unadjusted results by categorical
volume with propensity adjusted P values (Table 2). While
menundergoingRPLNDathighversuslowvolumehospitals
experienced fewer respiratory complications (4.2% versus
7.2%, P = .038), the frequency of cardiac, genitourinary,
wound, vascular, miscellaneous medical, and surgical com-
plications, and transfusion rates were similar using the
dichotomous volume deﬁnition. RPLND inpatient mortality
was less than .02%, median LOS was ﬁve days, most men
were routinely discharged home (97.8%), and the median
cost of RPLND was $10,490. While mortality, LOS, and dis-
charge status did not vary by dichotomous hospital volume,
median RPLND costs were greater at high versus low volume
hospitals ($11,365 versus $9,930, P<. 001).
When outcomes were assessed by hospital volume as a
continuous variable, more notable diﬀerences were observedAdvances in Urology 3
Table 1: Characteristics of the RPLND study population.
Total Hospital volume
P value Low High
n = 993 n = 512 n = 481
Age
Mean (SD) 30.9 (9.4) 31.7 (9.7) 30.4 (9.4) .006
Median (IQR) 29.0 (23.0–36.0) 31.0 (24.0–38.0) 27.0 (23.0–35.0) .003
Range 18–78 18.0–78.0 18.0–66.0
Race (n/%)
White 614 (61.8) 283 (55.3) 331 (68.8)
<.001 Non-White 164 (16.5) 83 (16.2) 81 (16.8)
Missing 212 (21.7) 145 (28.5) 69 (14.4)
Primary Payer (n/%)
Private 709 (71.4) 370 (72.3) 339 (70.5)
.017 Medicare 38 (3.8) 11 (2.2) 27 (5.6)
Medicaid/Other 246 (24.8) 131 (25.6) 115 (23.9)
Income Quartile (n/%)
$1–$38,999 154 (21.4) 72 (20.8) 82 (21.7)
.050 $39,000–$47,999 173 (23.9) 98 (28.2) 75 (19.8)
$48,000–$62,999 195 (26.9) 83 (23.9) 112 (29.6)
$63,000+ 203 (28.0) 94 (27.1) 109 (28.8)
Hospital Type (n/%)
Rural 20∗ (2) 20∗ (3) 0
<.001 Urban Non-Teaching 180∗ (18) 180∗ (35) DS (2)
Urban Teaching 790∗ (80) 320∗ (62) 470∗ (98)
Hospital Bed Size (n/%)
Small 88 (8.9) 41 (8.0) 47 (9.8)
<.001 Medium 124 (12.5) 93 (18.2) 31 (6.4)
Large 781 (78.7) 378 (73.8) 403 (83.8)
Hospital Region (n/%)
Northeast 186 (18.7) 102 (19.9) 84 (17.5)
.337 Midwest 246 (24.8) 128 (25.0) 118 (24.5)
South 325 (32.7) 172 (33.6) 153 (31.8)
West 236 (23.8) 110 (21.5) 126 (26.2)
Comorbidity (n/%)
None 452 (45.5) 241 (47.1) 211 (43.9)
.076 One 400 (40.3) 190 (37.1) 210 (43.7)
Multiple 141 (14.2) 81 (15.8) 60 (12.5)
Abbreviations: SD: standard deviation, IQR: interquartile range, DS: data suppressed per NIS for 0 <n<11.
∗n rounded to nearest 10 to prevent calculation of suppressed data, % based on rounded.
n,n u m b e r sm a yn o ta d du pt ot o t a la n d%m a yn o ta d du pt o1 0 0d u et or o u n d i n g .
(Table 3). For instance, higher hospital volume was asso-
ciated with fewer respiratory, miscellaneous medical com-
plications and overall complications (all P ≤ .047). While
higher hospital volume was associated with a greater likeli-
hood for routine home discharge (P = .017), it was also
associated with more blood transfusions (P = .004) when
volume was assessed as a continuous rather than dichoto-
mous variable. There was no hospital volume relationship
withLOS,however,highercostswereassociatedwithincreas-
ing RPLND volume (P<. 001).
WhiletransfusionsandmostcomplicationsextendedLOS,
this was most pronounced for vascular and miscellaneous
medical complications, which prolonged hospitalization by
twoand2.5days,respectively(bothP ≤ .021,Table 4).Addi-
tionally, most complications were associated with a lower
likelihood of routine home discharge. In particular, wound
complications decreased routine discharge by 17.3% (P<
.001). Overall, complications increased median hospitaliza-
tion costs by $2,784, and all complications aside from wound
complications were associated with higher costs. Most not-
ably, cardiac and vascular complications increased hospital
costs by $6,322 and $6,405, respectively, and transfusions in-
creased costs by $5,933 (all P<. 001).
3.3. RPLND with Concurrent Operation. R P L N Dw i t hc o n -
current operations was associated with more complications
and transfusions, particularly RPLND with nephrectomy
(both P<. 001, Table 5). Men undergoing RPLND with con-
current orchiectomy and nephrectomy experienced greater4 Advances in Urology
Table 2: RPLND outcomes and costs by dichotomous hospital volume.
Total
Hospital volume
P value Low Low
n = 993 n = 512 n = 481
Complications (n/%)
Cardiac DS (0)∗ DS (0)∗ DS (0)∗ .678
Respiratory 57 (5.7) 37 (7.2) 20 (4.2) .040
Genitourinary 28 (2.8) 16 (3.1) 12 (2.5) .091
Wound 27 (2.7) 16 (3.1) 11 (2.3) .339
Vascular DS (0)∗ DS (0)∗ DS (0)∗ .631
Miscellaneous Medical 133 (13.4) 70 (13.7) 63 (13.1) .286
Miscellaneous Surgical 51 (5.1) 27 (5.3) 24 (5.0) .506
Death DS (0)∗ DS (0)∗ 0 .116
Any complication 246 (24.8) 138 (27.0) 108 (22.5) .246
Blood Transfusion (n/%) 34 (3.4) 11 (2.2) 23 (4.8) .064
Routine Discharge (n/%) 971 (97.8) 498 (97.3) 473 (98.3) .315
LOS (Median days/IQR) 5.0 (4.0–6.0) 5.0 (4.0–6.0) 5.0 (4.0–7.0) .391
Costs (Median/IQR)
$10,490
($7,792–
$14,969)
$9,930 ($6,933–$12,927) $11,365 ($8,394–$18,402) <.001
Abbreviations: DS: data suppressed per NIS for 0 <n<11, LOS: length of stay, IQR: interquartile range.
∗% rounded to nearest 5 to prevent calculation of suppressed data.
mortality and fewer routine discharges (both P<. 001). Sim-
ilarly, LOS increased with additional procedures (P<. 001).
Costs were also higher with additional procedures, particu-
larly for concurrent nephrectomy, with increments ranging
from $14,074 to $19,697 over RPLND alone (P<. 001).
4. Discussion
The relative low incidence of testis cancer (5.5 per 100,000
men) compared with more common genitourinary cancers
such as prostate cancer (156 per 100,000 men) [11]c o n t r i -
butestothechallengeofexploringRPLNDpopulation-based
outcomes. While published RPLND outcomes come largely
from experienced high volume hospitals [12–17], we found
that more than half of all RPLND are performed at hospitals
with volumes of less than three RPLND annually. Thus, with
a more stringent deﬁnition for “high volume” of >40 cases
per year, the vast majority of RPLND is performed at low
volume centers. Therefore published RPLND series may not
berepresentativeofcommunityoutcomes.Whilehigherpro-
vider volume is associated with improved outcomes for geni-
tourinary oncologic conditions including radical prostatec-
tomy, cystectomy, and nephrectomy [4], this eﬀect has yet to
be studied or demonstrated for RPLND. To our knowledge,
this is the ﬁrst population-based study to characterize
RPLNDpatternsofcare,outcomes,andcosts,andtodemon-
strate volume outcomes eﬀects.
Our study has several important ﬁndings. First, sociode-
mographic diﬀerences were observed between high versus
low volume hospitals. While a previous population-based
study demonstrated that RPLND utilization did not vary by
socioeconomic or racial backgrounds [3], our study demon-
strates that nonwhites with lower incomes were less likely
to undergo RPLND at high volume hospitals. For other
urologic cancers, higher provider volume is associated
with better outcomes and lower mortality [4]. Similarly,
several studies demonstrate improved survival for men with
metastatic testis cancer who were treated with chemotherapy
at higher volume centers [18–20]. This raises concern
whether minorities and lower income men have unequal
access to high volume centers and the comprehensive cancer
care they oﬀer, which has been shown to be disparate for
several other complex surgical procedures [21].
Second, while higher hospital volumes were associated
with fewer respiratory complications when assessing volume
dichotomously, RPLND volume assessed as a continuous
variable was associated with fewer overall and miscellaneous
medical complications, and more routine home discharges.
Unlike more common procedures where higher volume,
deﬁned in most series as ≥66th percentile, has been associ-
atedwithimprovedoutcomes[22–24],evena90thpercentile
volume appears to be too low a threshold for RPLND in
that signiﬁcant volume eﬀects are demonstrated only at
higher volume extremes for a procedure as uncommon
as RPLND. However, this is noted in the context where
higher volume centers are more likely to transfuse and incur
higher costs. A likely explanation for this may be that high
volume referral centers are more likely to treat complex
cases, including postchemotherapy and salvage resections.
RPLND with concurrent orchiectomy and/or nephrectomy
are more likely to be associated with these complex case
scenarios, and are referred to high volume hospitals, and
thus pose greater risks for complications. Our study likely
underestimates RPLND volume outcomes eﬀects due to ourAdvances in Urology 5
Table 3: RPLND outcomes by continuous hospital volume.
n Hospital volume P value
Median (IQR) Mean (SD)
Complications
Cardiac
Y DS 3.0 (1.0–5.0) 3.3 (2.4) .788
N 980∗ 2.0 (1.0–6.5) 14.3 (27.9)
Respiratory
Y 57 2.0 (1.0–3.0) 6.4 (16.3) .047
N 936 2.0 (1.0–6.5) 14.7 (28.2)
Genitourinary
Y 28 2.0 (1.0–5.0) 12.3 (27.9) .615
N 965 2.0 (1.0–6.5) 14.3 (27.8)
Wound
Y 27 2.0 (1.0–5.0) 5.5 (12.0) .483
N 966 2.0 (1.0–6.5) 14.5 (28.0)
Vascular
Y DS 1.0 (1.0–64.0) 23.7 (31.3) .446
N 990∗ 1.0 (1.0–6.5) 14.2 (27.7)
Miscellaneous Medical
Y 133 2.0 (1.0–6.0) 6.1 (14.0) .027
N 860 2.0 (1.0–6.5) 15.5 (29.1)
Miscellaneous Surgical
Y 51 2.0 (1.5–3.0) 4.5 (12.5) .468
N 942 2.0 (1.0–6.5) 14.7 (28.3)
Any complication
Y 246 2.5 (1.0–5.0) 7.0 (16.9) .004
N 747 2.0 (1.0–7.0) 16.6 (30.1)
Blood Transfusion
Y 34 4.5 (1.5–13.0) 22.2 (33.8) .004
N 959 2.0 (1.0–6.5) 13.9 (27.5)
Routine Discharge
Y 22 2.0 (1.0–6.5) 14.5 (28.0) .017
N 971 1.5 (1.0–3.0) 2.0 (1.4)
Abbreviation: IQR: Interquartile range, SD: Standard deviation, DS: Data suppressed per NIS for 0 <n<11.
∗n rounded to nearest 10 to prevent calculation of suppressed data.
inability to adjust for tumor stage and prior chemotherapy
use to diﬀerentiate case complexity.
Third, increased costs were associated with higher vol-
ume hospitals and concurrent operations. This may also be
related to the greater complexity of cases treated at high
volume centers, which are usually academic and focus on re-
search, teaching, and patient care that is irrespective of the
clinical or ﬁnancial risks [25]. Higher costs may also be attri-
butable to superior information technology and documenta-
tion of high volume hospitals, which may lead to improved
compliance with guidelines to improve reimbursements. It
has also been shown that hospitals with signiﬁcant market
shares are able to negotiate more competitive prices with in-
surers that could lead to higher costs [26].
Fourth, RPLND involving additional procedures, partic-
ularlytheuseofnephrectomy(3%),wereassociatedwithsig-
niﬁcantly more transfusions, complications, nonroutine dis-
charges, longer LOS, and higher hospital costs. It is note-
worthy that while high volume hospital cases required more
transfusions, which are associated with a cost increase of
nearly $6,000 more per case, the overall diﬀerential over low
volume hospitals was only $1,400, suggesting that higher
volume may also oﬀset costs associated with increased case
complexity and adverse outcomes. Despite these increased
costs,theseestimatesarelowerthanpreviouslyreportedhigh
volume hospital costs, where modiﬁed RPLND averaged
$16,900, and postchemotherapy RPLND averaged $28,600
[27].
Finally, complications and transfusions were associated
with increased LOS and costs, and fewer routine discharges.
While transfusions and cardiac and vascular complications
incurred the greatest cost increases, wound complications
yielded only $2,875 more in hospitalization costs but had the
greatest negative eﬀect on routine discharge. It is likely that
additional costs are passed onto skilled nursing facilities that
are not captured beyond the inpatient scope of NIS. How-
ever, our assessment of RPLND costs and outcomes are
relevant to the current U.S. healthcare debate. The recent
Medicare initiative to utilize “spending per beneﬁciary” as
a measure of hospital performance aims to incentivize6 Advances in Urology
Table 4: Length of stay, discharge status, and costs by clinical outcomes.
n LOS (Median days/IQR) P value Routine discharge (n/%) P-value Cost (median/IQR) P value
Complications
Cardiac
Y DS 6.0 (4.0–8.0) .084 DS (100) 1.000 $16,746 ($13,283–$28,343) .011
N 980∗ 5.0 (4.0–6.0) 962 (97.8) $10,424 ($7,747–$14,778)
Respiratory
Y 57 6.0 (5.0–8.0) <.001 53 (93.0) .033 $12,897 ($10,072–$18,276) .001
N 936 5.0 (4.0–6.0) 918 (98.1) $10,360 ($7,695–$14,602)
Genitourinary
Y 28 5.5 (4.0–9.0) .027 27 (96.4) .471 $12,883 ($10,358–$19,192) .021
N 965 5.0 (4.0–6.0) 944 (97.8) $10,394 ($7,738–$14,798)
Wound
Y 27 6.0 (4.0–15.0) .002 22 (81.5) <.001 $13,268 ($6,715–$34,577) .412
N 966 5.0 (4.0–6.0) 949 (98.2) $10,483 ($7,799–$14,788)
Vascular
Y DS 7.0 (7.0-8.0) .021 DS (100) 1.000 $16,823 ($10,948–$22,227) .047
N 990∗ 5.0 (4.0–6.0) 965 (97.8) $10,418 ($77,88–$14,807)
Miscellaneous Medical
Y 133 7.0 (5.0–9.0) <.001 126 (94.7) .020 $12,634 ($9,792–$18,276) <.001
N 860 4.5 (4.0–6.0) 845 (98.3) $10,168 ($7,608–$14,407)
Miscellaneous Surgical
Y 51 6.0 (5.0–8.0) <.001 47 (92.2) .023 $13,285 ($8,690–$24,662) .002
N 942 5.0 (4.0–6.0) 924 (98.1) $10,392 ($7,725–$14,611)
Any complication
Y 246 6.0 (5.0–8.0) <.001 234 (95.1) .001 $12,689 ($9,537–$18,814) <.001
N 747 4.0 (3.0–6.0) 737 (98.7) $9,905 ($7,558–$13,831)
Blood Transfusion
Y 34 6.0 (5.0–8.0) <.001 32 (94.1) .172 $16,293 ($16,293–$28,717) <.001
N 959 5.0 (4.0–6.0) 939 (97.9) $10,360 ($7,696–$14,424)
Abbreviation: LOS: length of stay, IQR: interquartile range, DS: data suppressed per NIS for 0 <n<11.
∗n rounded to nearest 10 to prevent calculation of suppressed data.
Table 5: Variation in RPLND complexity and outcomes.
RPLND RPLND + orchiectomy RPLND + nephrectomy RPLND + Orchiectomy +
nephrectomy P value
n = 993 n = 67 n = 27 n = DS
Death (n/%) DS (0)∗ 0 0 DS (15)∗ <.001
Any Complication (n/%) 246 (24.8) 24 (35.8) 17 (63.0) DS (30)∗ <.001
Blood Transfusion (n/%) 34 (3.4) DS (5)∗ DS (20)∗ DS (55)∗ <.001
Routine Discharge (n/%) 971 (97.8) 65 (97.0) 25 (92.6) DS (70)∗ <.001
LOS (Median days/IQR) 5 (4–6) 6 (4–8) 8 (6–10) 9 (6–15) <.001
Costs (Median/IQR) $10,490
($7,792–$14,969)
$15,478
($9,799–$25,340)
$30,187
($14,100–$37,034)
$24,564
($21,761–$43,698) <.001
Abbreviations: DS; data suppressed per NIS for 0 <n<11, LOS; length of stay, IQR; interquartile range.
∗% rounded to nearest 5 to prevent calculation of suppressed data.
hospitalsthatincurfewercomplicationsandlowercosts[28].
For RPLND and other complex operations, higher risk pa-
tients and those with greater case complexity are treated at
referral centers, which incur higher costs despite better clini-
cal outcomes. This policy raises concern that hospitals that
treat higher risk patients may be penalized under this para-
digm, though Medicare aims to adjust for disease severity.
Our study must be interpreted within the context of the
study design. First, administrative data are designed for bill-
ing purposes and may lack detailed clinical information; we
were unable to characterize tumor characteristics, disease
severity,andthuscouldnotdistinguishbetweenprimaryver-
sus postchemotherapy and salvage RPLND, which may aﬀect
patient selection and outcomes. While we minimized hetero-
geneity by excluding those admitted for metastatic disease or
undergoing concurrent operations from our primary
RPLND analyses, diﬀerences in case complexity remains
a potential confounder. However, administrative data areAdvances in Urology 7
accurate in capturing surgical complications [29], and
outcomes are standardized in contrast to comparison of case
series, which may vary in deﬁning complications and have
observerbiasinrecordingoutcomes.Second,thereismissing
race data for 21.7% of subjects. This may reﬂect diﬀerences
in actual patient demographics, whereby nonwhite minority
designations may not be speciﬁed, or may reﬂect systematic
diﬀerences in race identiﬁcation between low and high
volume hospitals. Third, NIS does not contain surgeon level
characteristics and we were unable to adjust for surgeon
experience. Fourth, NIS is limited to the inpatient setting,
and we were unable to assess long-term oncologic outcomes
such as recurrence and subsequent chemotherapy use, out-
patient complications, and costs. Finally, this is an observa-
tional study, and there may be additional unobserved con-
f o u n d e r st h a tw ew e r eu n a b l et oa d j u s tf o r .
5. Conclusion
This is the ﬁrst population-based study of RPLND utiliza-
tion, costs and outcomes that also characterizes hospital
volume outcomes eﬀects for RPLND. The majority of cases
are performed at hospitals with two or fewer RPLNDs per
year.Sociodemographicdiﬀerencesexistbetweenhighversus
low RPLND volume hospitals, which suggests an inequity in
access. Higher volume hospitals had higher transfusion rates
and incurred higher costs, possibly related to higher degrees
of surgical case complexity. Finally, high volume hospitals
had fewer complications and greater likelihood of routine
home discharge, despite likely greater case complexity.
Appendix
See the Supplementary Material available S1 online at:
doi:10.1155/2012/189823.
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